Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that targ...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1969855 |
| _version_ | 1797673344056688640 |
|---|---|
| author | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla |
| author_facet | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla |
| author_sort | Amal Hasan |
| collection | DOAJ |
| description | Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity. |
| first_indexed | 2024-03-11T21:43:11Z |
| format | Article |
| id | doaj.art-f0461e560bde47c7a454c443b46dbd49 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:43:11Z |
| publishDate | 2021-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-f0461e560bde47c7a454c443b46dbd492023-09-26T12:43:41ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-11-0117114121412510.1080/21645515.2021.19698551969855Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccinationAmal Hasan0Mohammad R. Al-Mulla1Jehad Abubaker2Fahd Al-Mulla3Dasman Diabetes InstituteKuwait UniversityDasman Diabetes InstituteDasman Diabetes InstituteCurrent vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.http://dx.doi.org/10.1080/21645515.2021.1969855sars-cov-2covid-19antibody-dependent enhancementneutralizationantibodiesvaccinespike protein |
| spellingShingle | Amal Hasan Mohammad R. Al-Mulla Jehad Abubaker Fahd Al-Mulla Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination Human Vaccines & Immunotherapeutics sars-cov-2 covid-19 antibody-dependent enhancement neutralization antibodies vaccine spike protein |
| title | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
| title_full | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
| title_fullStr | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
| title_full_unstemmed | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
| title_short | Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination |
| title_sort | early insight into antibody dependent enhancement after sars cov 2 mrna vaccination |
| topic | sars-cov-2 covid-19 antibody-dependent enhancement neutralization antibodies vaccine spike protein |
| url | http://dx.doi.org/10.1080/21645515.2021.1969855 |
| work_keys_str_mv | AT amalhasan earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT mohammadralmulla earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT jehadabubaker earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination AT fahdalmulla earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination |